LINC01193

Across TCGA pan-cancer cohorts, LINC01193 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC01193’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where LINC01193 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01193 is over-expressed in tumor, although a few such as PAAD and UCEC show the opposite, repressed pattern.

PRAD, PAAD, and UCEC are the cancer types where LINC01193 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01193 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.071	.002	2	view →
PAAD	Male	All	−0.025	.037	2	view →
UCEC	All	All	−0.013	.024	2	view →
KICH	All	All	+0.011	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LINC01193–PRAD

Open the PRAD breakdown →